CD47 and neoplasm: Employing CD47-overexpressed T-EVs instead of anti-CD47 antibodies to block CD47/SIRPα signal has the advantage that T-EVs can carry therapeutics to kill tumor cells around macrophages, thus “killing two birds with one stone”.